Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2216684 as adjunctive therapy to SSRI in prevention of symptom re-emergence in major depressive disorder
2010-024632-42Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing LY2216684 + SSRI with Placebo + SSRI (2 arms). Primary endpoint: Time to re-emergence of depressive symptoms. Started Mar 2011; status: completed.
02
Drugs
edivoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-024632-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024632-42.